Physician profile
Sheyla Randle
NPI 1992292528
$4,299.05
in general payments reported to CMS, 2019-2025
24 companies · $939 in 2025
The $939 reported for 2025 was more than what 79% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $871 · 2022: $758 · 2023: $802 · 2024: $929 · 2025: $939.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,670.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,670.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $673.96 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $656.99 | 2021-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $434.59 | 2021-2025 | Ingrezza |
| Alkermes, INC. | $381.27 | 2021-2025 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $261.16 | 2021-2025 | Rexulti, Abilify Mycite, Abilify Maintena |
| Corium, LLC | $227.94 | 2021-2024 | Azstarys |
| Janssen Pharmaceuticals, INC | $209.21 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $206.81 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $197.71 | 2022-2025 | Austedo Xr, Austedo, Austedo Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $161.19 | 2021-2025 | Trintellix |
| Vanda Pharmaceuticals INC. | $152.14 | 2023-2025 | Fanapt, Hetlioz |
| Lundbeck LLC | $119.07 | 2021-2025 | Rexulti |
| Neos Therapeutics, LP | $80.66 | 2022-2025 | Adzenys Xr-Odt |
| Indivior INC. | $74.34 | 2022-2023 | Perseris |
| E.R. Squibb & Sons, L.L.C. | $67.93 | 2025 | Cobenfy |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $66.19 | 2024 | Nuplazid |
| Ironshore Pharmaceuticals INC. | $62.02 | 2022-2023 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $51.31 | 2021-2025 | Qelbree |
| Merck Sharp & Dohme LLC | $49.17 | 2023 | Belsomra |
| Owp Pharmaceuticals, INC. | $44.50 | 2021 | |
| Eisai INC. | $41.79 | 2021-2022 | |
| Axsome Therapeutics, INC. | $33.01 | 2025 | Auvelity |
| Bausch Health US, LLC | $23.89 | 2022 | |
| Luye Pharma (USA) LTD. | $22.20 | 2025 | Erzofri Extended-Release |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheyla Randle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.